Tandem Diabetes Care (NSDQ:TNDM) posted first-quarter results that beat the revenue consensus on Wall Street but missed on earnings.
The San Diego-based company — maker of insulin pumps and other diabetes management devices — reported losses of -$14.9 million, or -25¢ per share, on sales of $97.9 million for the three months ended March 31, for a bottom-line sales growth of 46.4% compared with Q1 2019.
Earnings per share were -25¢, 8¢ behind The Street, where analysts were looking for sales of $84.5 million.
